Affinity Asset Advisors, LLC
- SEC CIK
- 0001773195
- Latest filing
- Aug 13, 2026
Holdings in Q3 2021
Holdings as of Sep 30, 2021, filed Nov 12, 2021. Long positions only; changes compare share counts with Q2 2021.
- Positions
- 66
- +4 vs. Q2 2021
- Portfolio value
- $251.2M
- +$41.3M (+19.7%) vs. Q2 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| Medicus Sciences AcquisitionG5960S124 | *W EXP 02/12/202 | 33,333 | $24.0K | <0.1% | 00.0% | Unchanged | – |
| Renovacor, Inc.75989E114 | *W EXP 99/99/999 | 75,000 | $60.0K | <0.1% | +75,000 | New | – |
| CRVSCorvus Pharmaceuticals, Inc. | COM | 50,000 | $242.0K | 0.1% | +50,000 | New | History |
| Aslan Pharmaceuticals Ltd04522R101 | ADS | 250,000 | $445.0K | 0.2% | +250,000 | New | – |
| KROSKeros Therapeutics, Inc. | COM | 12,500 | $495.0K | 0.2% | +12,500 | New | History |
| Beauty Health Co88331L116 | EQUITY WRT | 34,400 | $498.0K | 0.2% | −10,600−23.6% | Reduced | – |
| CTMXCytomX Therapeutics, Inc. | COM | 125,000 | $636.0K | 0.3% | +50,000+66.7% | Added | History |
| TNGXTango Therapeutics, Inc. | COM | 50,000 | $647.0K | 0.3% | +50,000 | New | History |
| XENEXenon Pharmaceuticals Inc. | COM | 50,000 | $764.0K | 0.3% | +50,000 | New | History |
| IPHAInnate Pharma SA | SPONSORED ADS | 125,000 | $771.0K | 0.3% | +125,000 | New | History |
| Achilles Therapeutics PLC00449L102 | SPONSORED ADS | 100,000 | $779.0K | 0.3% | +20,000+25.0% | Added | – |
| Immatics N.V.N44445117 | *W EXP 07/01/202 | 190,000 | $800.0K | 0.3% | 00.0% | Unchanged | – |
| LUNGPulmonx Corp | COM | 25,000 | $900.0K | 0.4% | −35,000−58.3% | Reduced | History |
| KDNYChinook Therapeutics, Inc. | COM | 74,341 | $949.0K | 0.4% | −125,659−62.8% | Reduced | History |
| RCORRenovacor, Inc. | COM | 115,000 | $1.04M | 0.4% | +115,000 | New | History |
| BHVNBiohaven Ltd. | COM | 7,500 | $1.04M | 0.4% | +7,500 | New | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 20,000 | $1.05M | 0.4% | 00.0% | Unchanged | History |
| FOLDAmicus Therapeutics, Inc. | COM | 111,400 | $1.06M | 0.4% | +111,400 | New | History |
| CELLBruker Cellular Analysis, Inc. | COM | 55,000 | $1.08M | 0.4% | +55,000 | New | History |
| ZYMEZymeworks Inc. | COM | 38,814 | $1.13M | 0.4% | +8,814+29.4% | Added | History |
| PCVXVaxcyte, Inc. | COM | 50,000 | $1.27M | 0.5% | 00.0% | Unchanged | History |
| SDGRSchrodinger, Inc. | COM | 25,000 | $1.37M | 0.5% | 00.0% | Unchanged | History |
| SNCEScience 37 Holdings, Inc. | COM | 150,000 | $1.47M | 0.6% | 00.0% | Unchanged | History |
| BFLYButterfly Network, Inc. | COM CL A | 150,000 | $1.57M | 0.6% | +50,000+50.0% | Added | History |
| MREOMereo BioPharma Group plc | SPON ADS | 650,000 | $1.57M | 0.6% | 00.0% | Unchanged | History |
| HZNPHorizon Therapeutics Public Ltd Co | SHS | 15,000 | $1.64M | 0.7% | −10,000−40.0% | Reduced | History |
| ALDXAldeyra Therapeutics, Inc. | COM | 197,759 | $1.74M | 0.7% | −2,241−1.1% | Reduced | History |
| AFIBAcutus Medical, Inc. | COM | 200,000 | $1.77M | 0.7% | +120,000+150.0% | Added | History |
| UTHRUnited Therapeutics Corp | COM | 10,000 | $1.85M | 0.7% | +10,000 | New | History |
| GBTGlobal Blood Therapeutics, Inc. | COM | 75,000 | $1.91M | 0.8% | +55,000+275.0% | Added | History |
| HARPHarpoon Therapeutics, Inc. | COM | 250,000 | $1.98M | 0.8% | +200,000+400.0% | Added | History |
| NTLAIntellia Therapeutics, Inc. | COM | 15,000 | $2.01M | 0.8% | +5,000+50.0% | Added | History |
| Gossamer Bio, Inc.38341PAA0 | NOTE 5.000% 6/0 | – | $2.09M | 0.8% | – | – | – |
| Bio Green Med Solution, Inc.23254L603 | COM | 400,000 | $2.11M | 0.8% | +20,000+5.3% | Added | – |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 40,154 | $2.17M | 0.9% | −9,846−19.7% | Reduced | History |
| RCKTRocket Pharmaceuticals, Inc. | COM | 80,228 | $2.40M | 1.0% | −39,772−33.1% | Reduced | History |
| Medicus Sciences AcquisitionG5960S108 | CL A SHS | 300,000 | $2.92M | 1.2% | 00.0% | Unchanged | – |
| Environmental Impact Acqu Co29408N106 | COM CL A | 300,000 | $2.97M | 1.2% | +300,000 | New | – |
| OBIOOrchestra BioMed Holdings, Inc. | ORD SHS | 300,000 | $2.97M | 1.2% | 00.0% | Unchanged | History |
| PRCTPROCEPT BioRobotics Corp | COM | 78,534 | $3.00M | 1.2% | +78,534 | New | History |
| Bellus Health Inc New07987C204 | COM NEW | 532,030 | $3.27M | 1.3% | +232,030+77.3% | Added | – |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 203,183 | $3.39M | 1.4% | +136,226+203.5% | Added | History |
| Trillium Therapeutics Inc.89620X506 | COM NEW | 200,000 | $3.51M | 1.4% | +200,000 | New | – |
| NSTGNS Wind Down Co., Inc. | COM | 75,000 | $3.60M | 1.4% | +60,000+400.0% | Added | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 150,000 | $3.70M | 1.5% | +50,000+50.0% | Added | History |
| ESTAEstablishment Labs Holdings Inc. | COM | 60,000 | $4.29M | 1.7% | +40,000+200.0% | Added | History |
| CYTKCytokinetics Inc | COM NEW | 125,000 | $4.47M | 1.8% | +55,000+78.6% | Added | History |
| CRISCuris Inc | COM NEW | 575,000 | $4.50M | 1.8% | −75,000−11.5% | Reduced | History |
| TVTXTravere Therapeutics, Inc. | COM | 200,000 | $4.85M | 1.9% | +200,000 | New | History |
| MRTXMirati Therapeutics, Inc. | COM | 27,500 | $4.87M | 1.9% | +27,500 | New | History |
| ZNTLZentalis Pharmaceuticals, Inc. | COM | 77,500 | $5.17M | 2.1% | −64,918−45.6% | Reduced | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 35,910 | $5.72M | 2.3% | +15,910+79.6% | Added | History |
| NAUTNautilus Biotechnology, Inc. | COM | 975,000 | $5.99M | 2.4% | +75,000+8.3% | Added | History |
| ARYDARYA Sciences Acquisition Corp IV | CL A | 600,000 | $6.04M | 2.4% | −100,000−14.3% | Reduced | History |
| XLRNAcceleron Pharma Inc | COM | 35,350 | $6.08M | 2.4% | −19,650−35.7% | Reduced | History |
| ACRSAclaris Therapeutics, Inc. | COM | 350,000 | $6.30M | 2.5% | +75,000+27.3% | Added | History |
| ARYEARYA Sciences Acquisition Corp V | CLASS A ORD SHS | 702,500 | $6.94M | 2.8% | +702,500 | New | History |
| Retrophin Inc761299AB2 | NOTE 2.500% 9/1 | – | $7.06M | 2.8% | – | – | – |
| OCULOcular Therapeutix, Inc | COM | 750,000 | $7.50M | 3.0% | +500,000+200.0% | Added | History |
| CERECerevel Therapeutics Holdings, Inc. | COM | 259,966 | $7.67M | 3.1% | +59,966+30.0% | Added | History |
| SWTXSpringWorks Therapeutics, Inc. | COM | 126,013 | $7.99M | 3.2% | +101,013+404.1% | Added | History |
| KURAKura Oncology, Inc. | COM | 530,000 | $9.93M | 4.0% | +105,000+24.7% | Added | History |
| NARIInari Medical, Inc. | Stock | 135,000 | $10.9M | 4.4% | +50,000+58.8% | Added | History |
| MORFMorphic Holding, Inc. | COM | 270,755 | $15.3M | 6.1% | +24,554+10.0% | Added | History |
| VINCVincerx Pharma, Inc. | COM NEW | 1,005,000 | $16.3M | 6.5% | +166,689+19.9% | Added | History |
| BBIOBridgeBio Pharma, Inc. | COM | 654,435 | $30.7M | 12.2% | +104,435+19.0% | Added | History |
Options (7)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| State Street SPDR S&P Biotech ETF78464A870 | ETF | $88.0M | – |
| SPYSPDR S&P 500 ETF Trust | ETF | $42.9M | – |
| FLNAFilana Therapeutics, Inc. | COM | $4.66M | – |
| EDITEditas Medicine, Inc. | COM | $4.11M | – |
| RFLRafael Holdings, Inc. | COM CL B | $3.11M | – |
| SEERSeer, Inc. | COM CL A | – | $1.73M |
| IMVTImmunovant, Inc. | COM | – | $261.0K |
Sold out since Q2 2021 (14)
Positions held at the end of Q2 2021 that are gone from this filing.
| Security | Class | Shares in Q2 2021 | Value in Q2 2021 | % of portfolio in Q2 2021 | History |
|---|---|---|---|---|---|
| PTGXProtagonist Therapeutics, Inc | COM | 140,100 | $6.29M | 3.0% | History |
| MGNXMacrogenics Inc | COM | 80,000 | $2.15M | 1.0% | History |
| EPIXESSA Pharma Inc. | COM NEW | 70,000 | $2.00M | 1.0% | History |
| AXSMAxsome Therapeutics, Inc. | COM | 25,000 | $1.69M | 0.8% | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 50,000 | $1.20M | 0.6% | History |
| CGEMCullinan Therapeutics, Inc. | COM | 45,000 | $1.16M | 0.6% | History |
| MRSNMersana Therapeutics, Inc. | COM | 85,000 | $1.15M | 0.5% | History |
| BCTG Acquisition Corp05492W103 | COM | 100,000 | $1.14M | 0.5% | – |
| Cerevel Therapeutics HLDNG I15678U102 | *W EXP 06/09/202 | 72,466 | $1.04M | 0.5% | – |
| QSIQuantum-Si Inc | COM CL A | 75,000 | $920.0K | 0.4% | History |
| Chardan Healthcr Acqstn 2 Co15957T206 | UNIT 99/99/9999 | 75,000 | $819.0K | 0.4% | – |
| ITOSiTeos Therapeutics, Inc. | COM | 25,000 | $641.0K | 0.3% | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 10,000 | $632.0K | 0.3% | History |
| CVRXCVRx, Inc. | COM | 7,500 | $210.0K | 0.1% | History |